Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System

Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):69-71. doi: 10.1093/ehjcvp/pvx038.

Authors

Vasily Cherepanov¹, Seth D Fortmann¹, Moo Hyun Kim², Thomas A Marciniak³, Oleg Litvinov¹, Kyryl Mihalev⁴, Victor L Serebruany^{1

5}

Affiliations

¹ HeartDrug Research LLC, 7600 Osler Drive, Suite 307, Towson, MD 21294, USA.
² Dong-A University, Hospital, Division of Cardiology, 26 Daesingongwon-ro, Seo-gu, Busan 602-812, South Korea.
³ 39344 Hatteras Drive Bethany Beach, DE 19930, USA.
⁴ Center for Preventive and Clinical Medicine, Verhnyaya Str. 5, Kiev, 01014, Ukraine.
⁵ Division of Neurology, Johns Hopkins University,14110 Rover Mill Road, West Friendship, MD 21794, USA.

PMID: 29272379
DOI: 10.1093/ehjcvp/pvx038

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adverse Drug Reaction Reporting Systems / statistics & numerical data*
Cardiovascular Diseases / drug therapy*
Clopidogrel / adverse effects*
Humans
Platelet Aggregation Inhibitors / adverse effects
Prasugrel Hydrochloride / adverse effects*
Ticagrelor / adverse effects*
United States
United States Food and Drug Administration*

Substances

Platelet Aggregation Inhibitors
Clopidogrel
Prasugrel Hydrochloride
Ticagrelor